text:
All Topics
Biotech Business
Biotech Products
Drug Discovery
Infectious Diseases
Mental Health
Public Health
Track topics on Twitter Track topics that are important to you
LIPITOR (atorvastatin calcium) is a synthetic lipid-lowering agent. Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
Atorvastatin calcium is [R-(R*, R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate. The empirical formula of atorvastatin calcium is (CHFNO)Ca•3HO and its molecular weight is 1209.42. Its structural formula is:
Atorvastatin calcium is a white to off-white crystalline powder that is insoluble in aqueous solutions of pH 4 and below. Atorvastatin calcium is very slightly soluble in distilled water, pH 7.4 phosphate buffer, and acetonitrile, slightly soluble in ethanol, and freely soluble in methanol.
LIPITOR tablets for oral administration contain 10, 20, 40 or 80 mg atorvastatin and the following inactive ingredients: calcium carbonate, USP; candelilla wax, FCC; croscarmellose sodium, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and apolipoprotein B (apo B) promote human atherosclerosis and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.
In animal models, LIPITOR lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL; LIPITOR also reduces LDL production and the number of LDL particles. LIPITOR reduces LDL-C in some patients with homozygous familial hypercholesterolemia (FH), a population that rarely responds to other lipid-lowering medication(s).
A variety of clinical studies have demonstrated that elevated levels of total-C, LDL-C, and apo B (a membrane complex for LDL-C) promote human atherosclerosis. Similarly, decreased levels of HDL-C (and its transport complex, apo A) are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C, and inversely with the level of HDL-C.
LIPITOR reduces total-C, LDL-C, and apo B in patients with homozygous and heterozygous FH, nonfamilial forms of hypercholesterolemia, and mixed dyslipidemia. LIPITOR also reduces VLDL-C and TG and produces variable increases in HDL-C and apolipoprotein A-1. LIPITOR reduces total-C, LDL-C, VLDL-C, apo B, TG, and non-HDL-C, and increases HDL-C in patients with isolated hypertriglyceridemia. LIPITOR reduces intermediate density lipoprotein cholesterol (IDL-C) in patients with dysbetalipoproteinemia.
Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate density lipoprotein (IDL), and remnants, can also promote atherosclerosis. Elevated plasma triglycerides are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease. As such, total plasma TG has not consistently been shown to be an independent risk factor for CHD. Furthermore, the independent effect of raising HDL or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.
Atorvastatin as well as some of its metabolites are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage rather than systemic drug concentration correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response (see DOSAGE AND ADMINISTRATION).
Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether atorvastatin is given with or without food. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration (see DOSAGE AND ADMINISTRATION).
Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin is likely to be secreted in human milk (see CONTRAINDICATIONS, Pregnancy and Lactation, and PRECAUTIONS, Nursing Mothers).
Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme (see PRECAUTIONS, Drug Interactions). In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.
Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration.
Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Clinical data suggest a greater degree of LDL-lowering at any dose of drug in the elderly patient population compared to younger adults (see PRECAUTIONS section; Geriatric Use subsection).
Pharmacokinetic data in the pediatric population are not available.
Plasma concentrations of atorvastatin in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with LIPITOR between men and women.
Renal disease has no influence on the plasma concentrations or LDL-C reduction of atorvastatin; thus, dose adjustment in patients with renal dysfunction is not necessary (see DOSAGE AND ADMINISTRATION).
While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of atorvastatin since the drug is extensively bound to plasma proteins.
In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease (see CONTRAINDICATIONS).
In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the effect of LIPITOR (atorvastatin calcium) on fatal and non-fatal coronary heart disease was assessed in 10,305 hypertensive patients 40–80 years of age (mean of 63 years), without a previous myocardial infarction and with TC levels ≤251 mg/dl (6.5 mmol/l). Additionally all patients had at least 3 of the following cardiovascular risk factors: male gender (81.1%), age >55 years (84.5%), smoking (33.2%), diabetes (24.3%), history of CHD in a first-degree relative (26%), TC:HDL >6 (14.3%), peripheral vascular disease (5.1%), left ventricular hypertrophy (14.4%), prior cerebrovascular event (9.8%), specific ECG abnormality (14.3%), proteinuria/albuminuria (62.4%). In this double-blind, placebo-controlled study patients were treated with anti-hypertensive therapy (Goal BP <140/90 mm Hg for non-diabetic patients, <130/80 mm Hg for diabetic patients) and allocated to either LIPITOR 10 mg daily (n=5168) or placebo (n=5137), using a covariate adaptive method which took into account the distribution of nine baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients were followed for a median duration of 3.3 years.
The effect of 10 mg/day of LIPITOR on lipid levels was similar to that seen in previous clinical trials.
LIPITOR significantly reduced the rate of coronary events [either fatal coronary heart disease (46 events in the placebo group vs. 40 events in the LIPITOR group) or nonfatal MI (108 events in the placebo group vs. 60 events in the LIPITOR group)] with a relative risk reduction of 36% [(based on incidences of 1.9% for LIPITOR vs. 3.0% for placebo), p=0.0005 (see Figure 1)]. The risk reduction was consistent regardless of age, smoking status, obesity or presence of renal dysfunction. The effect of LIPITOR was seen regardless of baseline LDL levels. Due to the small number of events, results for women were inconclusive.
LIPITOR also significantly decreased the relative risk for revascularization procedures by 42%. Although the reduction of fatal and non-fatal strokes did not reach a pre-defined significance level (p=0.01), a favorable trend was observed with a 26% relative risk reduction (incidences of 1.7% for LIPITOR and 2.3% for placebo). There was no significant difference between the treatment groups for death due to cardiovascular causes (p=0.51) or noncardiovascular causes (p=0.17).
In the Collaborative Atorvastatin Diabetes Study (CARDS), the effect of LIPITOR (atorvastatin calcium) on cardiovascular disease (CVD) endpoints was assessed in 2838 subjects (94% White, 68% male), ages 40–75 with type 2 diabetes based on WHO criteria, without prior history of cardiovascular disease and with LDL≤ 160 mg/dL and TG ≤600 mg/dL. In addition to diabetes, subjects had 1 or more of the following risk factors: current smoking (23%), hypertension (80%), retinopathy (30%), or microalbuminuria (9%) or macroalbuminuria (3%). No subjects on hemodialysis were enrolled in the study. In this multicenter, placebo-controlled, double-blind clinical trial, subjects were randomly allocated to either LIPITOR 10 mg daily (1429) or placebo (1411) in a 1:1 ratio and were followed for a median duration of 3.9 years. The primary endpoint was the occurrence of any of the major cardiovascular events: myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke. The primary analysis was the time to first occurrence of the primary endpoint.
Baseline characteristics of subjects were: mean age of 62 years, mean HbA7.7%; median LDL-C 120 mg/dL; median TC 207 mg/dL; median TG 151 mg/dL; median HDL-C 52mg/dL.
The effect of LIPITOR 10 mg/ day on lipid levels was similar to that seen in previous clinical trials.
LIPITOR significantly reduced the rate of major cardiovascular events (primary endpoint events) (83 events in the LIPITOR group vs. 127 events in the placebo group) with a relative risk reduction of 37%, HR 0.63, 95% CI (0.48,0.83) (p=0.001) (see Figure 2). An effect of LIPITOR was seen regardless of age, sex, or baseline lipid levels.
LIPITOR significantly reduced the risk of stroke by 48% (21 events in the LIPITOR group vs 39 events in the placebo group), HR 0.52, 95% CI (0.31,0.89) (p=0.016) and reduced the risk of MI by 42% (38 events in the LIPITOR group vs 64 events in the placebo group), HR 0.58, 95.1% CI (0.39, 0.86) (p=0.007). There was no significant difference between the treatment groups for angina, revascularization procedures, and acute CHD death.
There were 61 deaths in the LIPITOR group vs 82 deaths in the placebo group, (HR 0.73, p=0.059).
In the Treating to New Targets Study (TNT), the effect of LIPITOR 80 mg/day vs. LIPITOR 10 mg/day on the reduction in cardiovascular events was assessed in 10,001 subjects (94% white, 81% male, 38% ≥65 years) with clinically evident coronary heart disease who had achieved a target LDL-C level <130 mg/dL after completing an 8-week, open-label, run-in period with LIPITOR 10 mg/day. Subjects were randomly assigned to either 10 mg/day or 80 mg/day of LIPITOR and followed for a median duration of 4.9 years. The primary endpoint was the time-to-first occurrence of any of the following major cardiovascular events (MCVE): death due to CHD, non-fatal myocardial infarction, resuscitated cardiac arrest, and fatal and non-fatal stroke. The mean LDL-C, TC, TG, non-HDL and HDL cholesterol levels at 12 weeks were 73, 145, 128, 98 and 47 mg/dL during treatment with 80 mg of LIPITOR and 99, 177, 152, 129 and 48 mg/dL during treatment with 10 mg of LIPITOR.
Treatment with LIPITOR 80 mg/day significantly reduced the rate of MCVE (434 events in the 80mg/day group vs 548 events in the 10 mg/day group) with a relative risk reduction of 22%, HR 0.78, 95% CI (0.69,0.89), p=0.0002 (see Figure 3 and Table 1). The overall risk reduction was consistent regardless of age (<65, ≥65) or gender.
Of the events that comprised the primary efficacy endpoint, treatment with LIPITOR 80 mg/day significantly reduced the rate of nonfatal, non-procedure related MI and fatal and non-fatal stroke, but not CHD death or resuscitated cardiac arrest (Table 1). Of the predefined secondary endpoints, treatment with LIPITOR 80 mg/day significantly reduced the rate of coronary revascularization, angina and hospitalization for heart failure, but not peripheral vascular disease. The reduction in the rate of CHF with hospitalization was only observed in the 8% of patients with a prior history of CHF.
There was no significant difference between the treatment groups for all-cause mortality (Table 1). The proportions of subjects who experienced cardiovascular death, including the components of CHD death and fatal stroke were numerically smaller in the LIPITOR 80 mg group than in the LIPITOR 10 mg treatment group. The proportions of subjects who experienced noncardiovascular death were numerically larger in the LIPITOR 80 mg group than in the LIPITOR 10 mg treatment group.
In the Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study (IDEAL), treatment with LIPITOR 80 mg/day was compared to treatment with simvastatin 20–40 mg/day in 8,888 subjects up to 80 years of age with a history of CHD to assess whether reduction in CV risk could be achieved. Patients were mainly male (81%), white (99%) with an average age of 61.7 years, and an average LDL-C of 121.5 mg/dL at randomization; 76% were on statin therapy. In this prospective, randomized, open-label, blinded endpoint (PROBE) trial with no run-in period, subjects were followed for a median duration of 4.8 years. The mean LDL-C, TC, TG, HDL and non-HDL cholesterol levels at Week 12 were 78, 145, 115, 45 and 100 mg/dL during treatment with 80 mg of LIPITOR and 105, 179, 142, 47 and 132 mg/dL during treatment with 20–40 mg of simvastatin.
There was no significant difference between the treatment groups for the primary endpoint, the rate of first major coronary event (fatal CHD, nonfatal MI and resuscitated cardiac arrest): 411 (9.3%) in the LIPITOR 80 mg/day group vs. 463 (10.4%) in the simvastatin 20–40 mg/day group, HR 0.89, 95% CI ( 0.78,1.01), p=0.07.
There were no significant differences between the treatment groups for all-cause mortality: 366 (8.2%) in the LIPITOR 80 mg/day group vs. 374 (8.4%) in the simvastatin 20–40 mg/day group. The proportions of subjects who experienced CV or non-CV death were similar for the LIPITOR 80 mg group and the simvastatin 20–40 mg group.
|Figure 1: Effect of LIPITOR 10 mg/day on Cumulative Incidence of Nonfatal Myocardial Infarction or Coronary Heart Disease Death (in ASCOT-LLA)
|Figure 2. Effect of LIPITOR 10 mg/day on Time to Occurrence of Major Cardiovascular Event (myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke) in CARDS.
|Figure 3. Effect of LIPITOR 80 mg/day vs.10 mg/day on Time to Occurrence of Major Cardiovascular Events (TNT)
|Atorvastatin 10
|Atorvastatin 80
|HR=hazard ratio; CHD=coronary heart disease; CI=confidence interval; MI=myocardial infarction; CHF=congestive heart failure;
|CV=cardiovascular; PVD=peripheral vascular disease; CABG=coronary artery bypass graft
|Confidence intervals for the Secondary Endpoints were not adjusted for multiple comparisons
|First major cardiovascular endpoint
|0.78 (0.69, 0.89)
|Components of the Primary Endpoint
|CHD death
|0.80 (0.61, 1.03)
|Nonfatal, non-procedure related MI
|0.78 (0.66, 0.93)
|Resuscitated cardiac arrest
|0.96 (0.56, 1.67)
|Stroke (fatal and non-fatal)
|0.75 (0.59, 0.96)
|First CHF with hospitalization
|0.74 (0.59, 0.94)
|First PVD endpoint
|0.97 (0.83, 1.15)
| First CABG or other coronary revascularization procedure
|0.72 (0.65, 0.80)
| First documented angina endpoint
|0.88 (0.79, 0.99)
|All cause mortality
|1.01 (0.85, 1.19)
|Components of all cause mortality
|Cardiovascular death
|0.81 (0.64, 1.03)
|Noncardiovascular death
|1.25 (0.99, 1.57)
|Cancer death
|1.13 (0.83, 1.55)
|Other non-CV death
|1.35 (0.91, 2.00)
| Suicide, homicide and other
traumatic non-CV death
|1.67 (0.73, 3.82)
LIPITOR reduces total-C, LDL-C, VLDL-C, apo B, and TG, and increases HDL-C in patients with hypercholesterolemia and mixed dyslipidemia. Therapeutic response is seen within 2 weeks, and maximum response is usually achieved within 4 weeks and maintained during chronic therapy.
LIPITOR is effective in a wide variety of patient populations with hypercholesterolemia, with and without hypertriglyceridemia, in men and women, and in the elderly. Experience in pediatric patients has been limited to patients with homozygous FH. In two multicenter, placebo-controlled, dose-response studies in patients with hypercholesterolemia, LIPITOR given as a single dose over 6 weeks significantly reduced total-C, LDL-C, apo B, and TG (Pooled results are provided in Table 2).
In patients with Fredrickson Types IIa and IIb hyperlipoproteinemia pooled from 24 controlled trials, the median (25 and 75 percentile) percent changes from baseline in HDL-C for atorvastatin 10, 20, 40, and 80 mg were 6.4 (-1.4, 14), 8.7(0, 17), 7.8(0, 16), and 5.1 (-2.7, 15), respectively. Additionally, analysis of the pooled data demonstrated consistent and significant decreases in total-C, LDL-C, TG, total-C/HDL-C, and LDL-C/HDL-C.
In three multicenter, double-blind studies in patients with hypercholesterolemia, LIPITOR was compared to other HMG-CoA reductase inhibitors. After randomization, patients were treated for 16 weeks with either LIPITOR 10 mg per day or a fixed dose of the comparative agent (Table 3).
The impact on clinical outcomes of the differences in lipid-altering effects between treatments shown in Table 3 is not known. Table 3 does not contain data comparing the effects of atorvastatin 10 mg and higher doses of lovastatin, pravastatin, and simvastatin. The drugs compared in the studies summarized in the table are not necessarily interchangeable.
|Apo B
| Treatment
(Daily Dose)
|Apo B
|Study 1
|Atorvastatin 10 mg
| -27
| -36
| -28
| -17
| -37
|Lovastatin 20 mg
|- 6
| 95% CI for Diff
|-9.2, -6.5
|-10.7, -7.1
|-10.0, -6.5
|-15.2, -7.1
|-1.7, 2.0
|-11.1, -7.1
|Study 2
|Atorvastatin 10 mg
| -25
| -35
| -27
| -17
| -36
|Pravastatin 20 mg
|- 9
| 95% CI for Diff
|-10.8, -6.1
|-14.5, -8.2
|-13.4, -7.4
|-14.1, -0.7
|-4.9, 1.6
|-11.5, -4.1
|Study 3
|Atorvastatin 10 mg
| -29
| -37
| -34
| -23
| -39
|Simvastatin 10 mg
| 95% CI for Diff
|-8.7, -2.7
|-10.1, -2.6
|-8.0, -1.1
|-15.1, -0.7
|-4.3, 3.9
|-9.6, -1.9
The response to LIPITOR in 64 patients with isolated hypertriglyceridemia treated across several clinical trials is shown in the table below. For the atorvastatin-treated patients, median (min, max) baseline TG level was 565 (267–1502).
| Placebo
| Atorvastatin 10 mg
| Atorvastatin 20 mg
| Atorvastatin 80 mg
|-12.4 (-36.6, 82.7)
|-41.0 (-76.2, 49.4)
|-38.7 (-62.7, 29.5)
|-51.8 (-82.8, 41.3)
|-2.3 (-15.5, 24.4)
|-28.2 (-44.9, -6.8)
|-34.9 (-49.6, -15.2)
|-44.4 (-63.5, -3.8)
|3.6 (-31.3, 31.6)
|-26.5 (-57.7, 9.8)
|-30.4 (-53.9, 0.3)
|-40.5 (-60.6, -13.8)
|3.8 (-18.6, 13.4)
|13.8 (-9.7, 61.5)
|11.0 (-3.2, 25.2)
|7.5 (-10.8, 37.2)
|-1.0 (-31.9, 53.2)
|-48.8 (-85.8, 57.3)
|-44.6 (-62.2, -10.8)
|-62.0 (-88.2, 37.6)
|-2.8 (-17.6, 30.0)
|-33.0 (-52.1, -13.3)
|-42.7 (-53.7, -17.4)
|-51.5 (-72.9, -4.3)
The results of an open-label crossover study of 16 patients (genotypes: 14 apo E2/E2 and 2 apo E3/E2) with dysbetalipoproteinemia (Fredrickson Type III) are shown in the table below.
|Median % Change (min, max)
|Median (min, max) at Baseline (mg/dL)
|Atorvastatin 10 mg
|Atorvastatin 80 mg
|442 (225, 1320)
|-37 (-85, 17)
|-58 (-90, -31)
|678 (273, 5990)
|-39 (-92, -8)
|-53 (-95, -30)
|215 (111, 613)
|-32 (-76, 9)
|-63 (-90, -8)
|411 (218, 1272)
|-43 (-87, -19)
|-64 (-92, -36)
In a study without a concurrent control group, 29 patients ages 6 to 37 years with homozygous FH received maximum daily doses of 20 to 80 mg of LIPITOR. The mean LDL-C reduction in this study was 18%. Twenty-five patients with a reduction in LDL-C had a mean response of 20% (range of 7% to 53%, median of 24%); the remaining 4 patients had 7% to 24% increases in LDL-C. Five of the 29 patients had absent LDL-receptor function. Of these, 2 patients also had a portacaval shunt and had no significant reduction in LDL-C. The remaining 3 receptor-negative patients had a mean LDL-C reduction of 22%.
A-S Medication Solutions LLC
These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR. LIPITOR (atorvastatin calcium) Tablets for oral administ...
Lipitor [Rebel Distributors Corp]
These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR. LIPITOR (atorvastatin calcium) Tablets for oral adminis...
Lipitor [Med Health Pharma LLC.]
These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR. LIPITOR (atorvastatin calcium) Tablets for oral adminis...
These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR. LIPITOR (atorvastatin calcium) Tablets for oral adminis...
Lipitor [Parke-Davis Division of Pfizer Inc]
These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR. LIPITOR (atorvastatin calcium) Tablets for oral adminis...
The Effect of Lipitor on Aortic Stenosis
The purpose of this study is to find out if an approved medicine that is used to lower cholesterol called Lipitor can slow or stop progressive narrowing of the aortic heart valve in patien...
A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol
The purpose of this study is to determine the efficacy of Lipitor (Atorvastatin) for the treatment of PCOS with elevated LDL cholesterol.
Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.
Lipitor as a Treatment for Alzheimer's Disease
The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
The purpose of this study is to identify subjects who are highly sensitized with antibodies. It is difficult for these patients to find suitable kidneys. We propose to treat such patients...
Coenzyme Q10 protects against statin-induced myotoxicity in zebrafish larvae (Danio rerio).
3-Hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is the rate-limiting enzyme of the mevalonic acid pathway and is required for cholesterol biosynthesis and the synthesis of Coenzyme Q10 (CoQ10). Stati...
Enhanced diastereoselective synthesis of t-butyl 6-cyano-(3R,5R)-dihydroxyhexanoate by using aldo-keto reductase and glucose dehydrogenase co-producing engineered Escherichia coli.
t-Butyl 6-cyano-(3R,5R)-dihydroxyhexanoate ((3R,5R)-2) is a key chiral diol precursor of atorvastatin calcium (Lipitor®). We have constructed a Kluyveromyces lactis aldo-keto reductase mutant KlAKR-Y...
Engineering Streptomyces coelicolor carbonyl reductase for efficient synthesis of atorvastatin precursor.
ScCR1 has been shown to be a promising biocatalyst for the synthesis of an atorvastatin precursor, ethyl (S)-4-chloro-3-hydroxybutyrate. However, limitations of ScCR1 observed for practical applicatio...
Quick Links
Advanced Search | Login | Subscribe | RSS
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...
Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been as...
Search Drugs and Medication Database


text:
SAN FRANCISCO -- Catcher Michael Barrett reported a "pop" in his throwing elbow yesterday, departed the game in the sixth inning, then flunked a ligament stress test before the club sent him to San Diego for an MRI exam and further evaluation.
"He was in a great deal of pain," said General Manager Kevin Towers.
Barrett is to go on the disabled list, increasing the workload for catcher Josh Bard -- who has started five of eight games -- with Colt Morton due to arrive from Double-A San Antonio before the game Tuesday.
Towers said results of a stress test administered by a Giants doctor raised concerns that Barrett's ulnar collateral ligament is damaged, though to what degree was unknown.
Manager Bud Black said Barrett reported a "pop" in his elbow after making a throw to pitcher Greg Maddux. According to Towers, the catcher had been nagged by a shoulder ailment that may have led him to inadvertently adjust his throwing form, stressing the elbow.
Because Barrett reported a tingling sensation in the final two fingers on his right hand, doctors will try to determine if the problem is related to a nerve in the elbow, Towers said.
Towers, who had "Tommy John" surgery when he was a Triple-A pitcher, said it's too early to comment on whether the club is concerned that Barrett suffered a ligament tear that would require reconstructive elbow surgery.
Showing signs of rebounding from a poor second half with the Padres last season, Barrett had batted .394 in spring training with seven doubles. He has made three starts this season and is 3-for-8 with two walks.
"We're crossing our fingers that he's all right," Black said. "He's been nothing but a pleasure for me and the coaching staff. Everything we've asked, he's worked his tail off."
Said Towers: "You hate to see one of your core players go down. You just hope it's something where the ligament isn't damaged. He was looking pretty good this year."
Umpires to watch Peavy
Umpires will pay extra attention to Jake Peavy's right hand, Towers said he was told Monday by Bob Watson, baseball's vice president of on-field operations. The commissioner's office is aware of a photograph showing a dark substance on the forefinger, middle finger and thumb of Peavy's pitching hand, shortly after Peavy threw a two-hitter against the Dodgers on Saturday. The phone call from Watson, according to a major league official, didn't reflect anything "untoward" on Peavy's part but was a "general reinforcement" of rules forbidding a pitcher's use of substances such as pine tar.
"Bob said the umpires are going to keep a close eye on Jake, based on the allegation of the Los Angeles Dodgers," Towers said. "(Watson) said they are not doing an investigation."
Peavy, who said on Sunday that he's "not out there cheating," smiled and joked yesterday that outsiders "look for something" when a pitcher is doing well.
"There's no foul play here," Towers said.
The incident, and Watson's response, is similar to what occurred last year with Angels closer Francisco Rodriguez.

subset: commoncrawl


text:
Australian and New Zealand Gardening: BROMELIADS FOR NOVICES & ADDICTS MAY & June 2012, 5 by splinter1804
Communities > Forums
Image Copyright splinter1804
In reply to: BROMELIADS FOR NOVICES & ADDICTS MAY & June 2012
Forum: Australian and New Zealand Gardening
|<<< Previous photo
|Next photo >>>
splinter1804 wrote:
Hi everyone � Well I survived my day at �computer school� yesterday and didn�t get the cane once. I now have a good idea of the basic operation about setting up a �Power Point� presentation and I imagine I will pick up how to use the many other functions of the programme as I go along, so all in all a day not wasted as I thought it would have been.
Shirley � First up a bit more info about the Bill. �Foster�s Striate� which I didn�t know until a friend pointed it out to me. It was previously known as Bill. pyramidalis var. striata until the name was changed to �Foster�s striate�. Derek Butcher explains all about it in the BCR and ends the article with: (�Foster�s Striate� This replaces the old Billbergia pyramidalis var. striata). If you want to read the whole history about it go to: http://botu07.bio.uu.nl/bcg/bcr/index.php?genus=BILLBERGIA&i...
You�re more than welcome to a copy of the booklet but you need to send me a D-Mail with your Email address and as soon as I can get to a computer with email I�ll send it to you.
As you say with your Carcharodon �Tiger� (or as it�s now called 'Skotak�s Tiger� see: http://botu07.bio.uu.nl/bcg/bcr/index.php?genus=NEOREGELIA&i...) it needs more light. I have mine growing in the open and only move it away from summer sun from 12.00 noon to 2.00pm during the hot summer months. I find that any less light than that it reverts to green with the darker markings and loses that beautiful tiger colouring.
Karen � I couldn�t agree more with you about dogs, I got my first one when I was three and have always had one ever since. I dare say I�ll be getting another one soon, but not just yet. I hope you�re keeping warm and your plants are all doing well in this cooler time of the year.
Thank�s for the pic of the NOID, I suspected it was either a Vriesea or a Guzmania and it obviously is a Guzzie.
Mike � That�s a great specimen of Johannis �De Rolf�, it�s certainly a beautiful plant. What is the name of the Neo. below it in the bottom left corner? Neo �First Prize� I haven�t seen before around here either and that�s another one to add to my never ending �Wish List�.
Isn�t the albino Ensign beautiful? What a pity it doesn�t have just a little bit of green so you could develop a new cultivar. I don�t know much about genetics but I�m sure I read somewhere that they have to have a bit of visible green colouring to survive when removed from the mother plant. So I guess you just have to take lots of pic�s from every angle including underneath the leaves as well and just enjoy it while you can. Also thanks for the tip on growing Ensign. First I want to get a couple of plants that are from a different source than where I previously got them and I�ll try mounting one on a tree and with the other I�ll try Sue's way with the coir. I had given this some thought previously as I have had great success with other Aechmeas growing in coir chunks in undersized pots and hanging up.
Colleen � I don�t think I�d like to have a �pea super� down here. It�s bad enough when we sometimes get the ocean fogs. It�s really very �eerie� and everything seems so quiet and muffled and we can only see the tops of the Norfolk Island Pines above it in the next street; a most unnatural feeling.
I must say that bloke called �Nev� has been a bit slack in sending plants lately, and it�s just not you Colleen. I�ve just have a lot of other things of a higher priority to attend to at present but I will get around to sending them (and besides you don�t want them down there yet while it�s still so cold anyway).
Sue � You say you think Ensign may be a bit �cold tender� and you�re absolutely right as I know for a fact that the cold marks it down here unless it�s under cover, so I don�t know how Colleen would go as she gets colder weather than I. I must say you did well with your $10 purchase of Hallelujah. It�s one of the all time great Bill�s and you never have any trouble selling it when it�s grown properly.
I can�t help you with a name for your little Neo. But it�s certainly and �eye catcher� both in shape and colour.
A few pic's to finish with: 1st Bill. 'Curly Top', 2nd Neo. Aussie Dream 'Glorious', 3rd Neo. 'Lovely Lady', 4th. Neo (Sarmentosa x Cracker Jack) and 5th Neo 'Fairy Dust'
That�s about it for now, all the best, Nev.
[ Home |
About |
Advertise |
Media Kit |
Mission |
Featured Companies |
Submit an Article |
Tour |
Contact Us ]


text:
New class of Latino Hall honorees announced
New class of Latino Hall honorees announced
With that, the Latino Baseball Hall of Fame was formed.
And on Sunday morning at Yankee Stadium, where, a few hours prior, Latin stars like Jorge Posada, Robinson Cano, Alex Rodriguez and Mariano Rivera were on the field as the Yankees completed an American League Division Series sweep of the Twins, a second class of Latin immortals to be enshrined was announced.
Making up the "Contemporaries" group were pitchers Luis Tiant (born in Cuba), Fernando Valenzuela (Mexico) and Dennis Martinez (Nicaragua), catcher Manny Sanguillen (Panama), designated hitter Edgar Martinez (Puerto Rico), outfielder Rico Carty (Dominican Republic) and first baseman Andres Galarraga (Venezuela).
The "Veterans Committee" honorees were Adolfo Luque (Cuba), Chile Gomez (Mexico), Hector Lopez (Panama), Horacio Martinez (Dominican Republic) and Vidal Lopez (Venezuela).
The Latino Hall of Fame, which has the support of Major League Baseball, also enshrined a promoter, Venezuela's Oscar Negro Prieto, and handed out a couple of awards. Late Yankees owner George Steinbrenner won the Tommy Lasorda Award, given to a non-Latin figure who helps enhance Latin America's presence in the Majors, and Alex Rodriguez, who hit his 600th home run this season, took the LBHF Excellence Award.
"We have something here that is historically very important," LBHP President Roberto Weill said.
The Latino Baseball Hall of Fame was founded, thanks to the joint efforts of Weill, a Cuban-born international entrepreneur, and Rafael Avila, the Dodgers' Latin American scout who founded the first MLB Academy in the Dominican Republic, to honor the best Latinos in baseball and house their evidence and mementos of their accomplishments.
The Hall is headquartered in the Dominican Republic, at the Altos de Chavon at Casa de Campo in La Romana.
"We have so many Latin players [in the Majors] that this makes sense," Yankees executive vice president and chief international officer Felix Lopez said. "Anything we can do to actually make our players feel at home, it's something that just makes sense. And we need to do as much as we can to actually make all our players feel that this is a family environment, that we actually are embracing them."
Last year, the Hall of Fame, which has Lasorda as its director and goodwill ambassador, used five international channels to induct its inaugural class.
Making up the "Cooperstown Historic" group were Roberto Clemente (Puerto Rico), Juan Marichal (Dominican Republic), Luis Aparicio (Venezuela), Rod Carew (Panama), Orlando Cepeda (Puerto Rico), Tony Perez (Cuba), Martin Dihigo (Cuba), Jose de la Caridad Mendez (Cuba), Cristobal Torriente (Cuba), executive Alejandro Pompez (Cuba), journalist Eloy "Buck" Canel (Argentina), broadcaster Jaime Jarrin (Ecuador) and broadcaster Felo Ramirez (Cuba).
From the "Veterans Committee" (for those active before 1959) came Pancho Coimbre (Puerto Rico), Beto Avila (Mexico), Alfonso Carrasquel (Venezuela), Tetelo Vargas (Dominican) and Orestes Minoso (Cuba).
The "Permanent Induction Committee" (active after '59) sent Roberto Alomar (Puerto Rico), Dave Concepcion (Venezuela), Felipe Alou (Dominican), Camilo Pascual (Cuba) and Hector Espino (Mexico) to the Hall.
Now, another class will join them, with the new immortals set to be inducted on Feb. 12.
Based on numbers, the idea to honor Latin American ballplayers was easy, and so was housing the Hall of Fame in the Dominican Republic.
In 2010, 28.3 percent of the players on Opening Day Major League rosters were of Latin American descent, according to the University of Central Florida's Racial and Gender Report Card. That number stood at 13 percent in 1990 and has been on an upward trend ever since.
As for the Dominican Republic, the island nation, which boasts more players in the Majors than other Latin American country, holds 30 Major League training camps and has won a record 18 Caribbean Series trophies.
"Playing against the Dominican Republic," Weill said, "is like playing against the Yankees [for Caribbean teams]."
More information can be found at latinobaseballhall.com.
Alden Gonzalez is a reporter for MLB.com and writes an MLBlog, Gonzo and 'The Show'. Follow him on Twitter @Alden_Gonzalez. This story was not subject to the approval of Major League Baseball or its clubs. This story was not subject to the approval of Major League Baseball or its clubs.


text:
9 Comments
love The Endless Summer, and uhh zombies are cool too i guess..
nice concept! +1
haha, nice.
this would be ridiculously popular with surfers.
this is on teextile.com too
shiiba_art Artist from United States
@ joopit: I never said they did. Besides have you ever seen one? So then how do you know?
labyrindira Artist
splendid +1
vote for mine please http://www.designbyhumans.com/vote/detail/62889?page=2 ,
http://www.designbyhumans.com/vote/detail/62888?page=2 .. hope you guys enjoy
vincentrogel Artist
voted! +1 for the nice effect!
love the silhouette style!!! creepy!!! voted!!!
Check mine out too please:


text:
Look: Meow Sparkle Blues
Posted by Heather | Filed under Blue, Chanel, Fyrinnae, Guerlain, Looks, MAC, Make Up For Ever (MUFE), Meow
Fyrinnae and Meow make some amazing blues!
For this look I used:
- Eyes: NARS Eyeshadow Primer (primer), Fyrinnae Pixie Epoxy (base), Meow Blitzen (inner lid), Meow In-Laws (middle lid), Meow Sardonic (outer lid & crease), Fyrinnae Marshmallow Puffs (highlight), MAC Signature Blue Superslick Liquid Liner (upper lashline), Guerlain Blue Kohl (waterline), MUFE Smokey Lash mascara
- Cheeks: MAC Briar Rose Beauty Powder Blush
- Lips: Chanel Glossimer #122
See more pictures!! Read the rest of this entry »
Look: My #1 Favorite
Posted by Heather | Filed under Blue, Brown, Chanel, Guerlain, Looks, MAC, Make Up For Ever (MUFE), Meow, Red/Maroon, Smokey
No kidding, I think I've worn this exact look like 10 times already! I love it so much. It's sparkly, duochrome, shiny, bold, and very ME! I have so much makeup, that it is rare for me to do the same look even twice with the same shadows. Sure, I do the same types of gradients or color combos, but rarely with the exact same products. This is my exception. The shadow part is seemingly easy, because it's basically 2 colors with a highlight. However, foiling loose shadows is challenging for me – especially at the top where I need it to blend out and not have a harsh line. This time, I got it right!
For this look I used:
- Eyes: NARS Smudge Proof Eyeshadow Primer, MUFE Star Powder #955 (applied wet to lid), Meow Sardonic (applied wet to crease & above crease), Sugarpill Lumi (highlight), MUFE Aqualine 0L (upper lashline), MAC Undercurrent Pearlglide liner (upper lashline over black), Guerlain Loose Eye Kohl #3 Blue (waterline), MAC Haute & Naughty mascara
- Cheeks: MAC Sun & Moon Mineralize blush
- Lips: Chanel Glossimer #122
See more pictures!!! Come on…you kinda have to since this is my FAVORITE look!!! :-) Read the rest of this entry »
Nails: Ozotic Pro 505
Posted by Heather | Filed under Nails, Ozotic Pro
Rainbows of color in epic proportions. Ozotic Pro colors are only available in Australia, and these duo (multi) chromes are actually being discontinued. I guess it's something to do with the pigments no longer being made, because it cannot be for lack of sales or love for this type of polish. All of these pictures are of the same polish: #505. Some are taken with the flash, and some without. Different colors come out in different lights. Pinks, blues, purples, greens…you'll see every color in there. This is two coats over black (or navy blue…can't recall). The polish is sheer, and must be layered over a darker color to see the effect.
Amazing, isn't it?! See more pictures!! Read the rest of this entry »
Look: Blurple
Posted by Heather | Filed under Blue, Looks, MAC, Purple, Urban Decay
I believe most of these colors are from the MAC Liberty of London collection, which was a while ago. I'm totally loving this blue and purple blending together :-)
For this look I used:
- Eyes: UDPP Eden (primer), Mac Suave Intentions (inner lid), MAC Satellite Dreams (middle lid), MAC Contrast (outer lid & crease), MAC Almond Icing (highlight), MAC Mystery Kohl Power (upper lashline), UD 24/7 Binge (lower lashline), Chanel Inimitable mascara
- Cheeks: MAC Azalea Blossom
- Lips: MAC English Accents lipglass
See more pictures!!! Read the rest of this entry »


text:
Why See Russell Peters?
Russell Peters hits the Barclays Center in Brooklyn, NY, Closed November 10, 2012
This Canadian stand-up comic is one of the best-known comedians in his homeland and has been nominated for numerous awards. Yet somehow, the stratospheric fame that has embraced the likes of John Pinette, Dave Chapelle, Chris Rock and Jerry Seinfeld has somehow eluded him.
His humour focuses on issues such as politics, his early life in Canada, his Anglo-Indian heritage and breaking cultural stereotypes. His experiences with racism often punctuates his material, but he's defiant towards anybody accusing him of mining his racial identity for laughs. As he puts it, "I don't make the stereotypes - I just see them." His most famous internet clip to date talks about disciplining children; in fact, most of his international success was spawned by someone uploading his comedy special to Youtube.
Peters started out on the comedy circuit at age 19, working the underground clubs, driving thousands of kilometers between gigs and is a consummate traveler. A keen observer of everyday life, his worldwide tours have helped him cultivate a wide range of impersonations and accents. Now the third most successful touring comedian on the international circuit, Peters continuously upgrades and reinvents his material, ensuring that his jokes remains fresh, and the laughs remain unforced.
Additional Information
Performance date: 10 November 2012
What you thought
Seen Russell Peters? Loved it? Hated it?
Help your fellow New York City Theater visitors by leaving the first review!Write a review now
Additional Information
Spread the word!
Keep up to date!
Straight to your inbox
Please note: The term Barclays Center and/or Russell Peters as well as all associated graphics, logos, and/or other tradermarks, tradenames or copyrights are the property of the Barclays Center and/or Russell Peters and are used herein for factual descriptive purposes only. We are in no way associated with or authorized by the Barclays Center and/or Russell Peters and neither that entity nor any of its affiliates have licensed or endorsed us to sell tickets, goods and or services in conjunction with their events.


text:
Chevron Press Release - Chevron Updates Northern California Pilots On Claims
SAN FRANCISCO, July 11, 1994 -- Chevron says it will pay Northern California aviation gasoline customers for engine repairs or replacement and related costs if their engines operated with contaminated fuel accidentally distributed by Chevron last May.
"As the leading supplier of aviation fuel in the nation, we pride ourselves most on two things -- the quality, integrity and safety of our products and the positive relationships we have with our many thousands of customers," said Peter Kump, general manager of aviation sales for Chevron.
"As we've said over the last several weeks, we deeply regret that we had a problem with our aviation fuel. We have solved the problem that caused the contamination in the first place, and we have changed our procedures to ensure that we won't have such a problem in the future. We will continue to work with Chevron's aviation customers to ensure that they're compensated."
The contaminated fuel was caused by a leaky valve at Chevron's Richmond, Calif., refinery during a two-hour period on May 16. The valve allowed jet fuel to mix with aviation gasoline. One truckload of the contaminated fuel was delivered to two airports in Sacramento. Six more trucks went out the next day with fuel that was much less contaminated to Watsonville, Concord, Oakland and Petaluma.
When it learned of the problem, Chevron immediately undertook a methodical process to work with the FAA, engine manufacturers and with aircraft owners to ensure that all planes that may have fueled with the contaminated mixture were defueled, inspected and repaired if needed. And as a result of what's been learned over the last few weeks about engine damage and customer inconvenience, the company has decided to forego further in-depth testing and inspection and simply pay to repair or replace engines that were involved. Kump said claims will be handled the same for all six airports.
Owners of aircraft purchasing avgas from the six affected airports during the period when contaminated fuel was available will again be contacted individually by Chevron. Correspondence from Chevron to each aircraft owner will outline procedures for their claims.
Further background for editors and reporters:
In piston-driven engines, the contaminated fuel could cause malfunctions similar to "pinging" in car engines, but contrary to some media reports, can not cause an engine to explode.
The fuel involved is not used in military or commercial jets, which use kerosene-based jet fuel.
On May 31, a pilot notified Chevron that he had experienced an engine problem and that his fuel smelled of kerosene. Chevron immediately contacted the FAA and began notifying pilots, owners and airports of the problem. In all, more than 1,200 pilots and owners were notified by the end of June. Chevron encouraged the pilots and owners to have their aircraft fuel tanks pumped out and replenished and engines inspected, and repaired if necessary by their own mechanics, all at Chevron's expense.
Chevron also immediately began work to provide fuel meeting all avgas specifications to all six Northern California airports.
The company continues to maintain a toll-free phone number for pilots and owners to call if they have any questions. The number is (800) 424-4474.
Updated: July 1994


text:
ACParadise Network: American Cosplay Paradise American Cosplay Experience American Cosplay Snapshots
Cosplayer Becca Consuelo > Costume of Alice (Alice in Wonderland)
- Most Recent Photo
- 03-11-2014
- Series
- Alice in Wonderland
- Character
- Alice
- Year Completed:
- 2014
- Construction Difficulty:
- Easy
- Costume worn at:
- Aki-Con 2013
- Sakura-con 2013
About this Costume
- Construction Details:
When I wore Alice to Sakura-con I didn't wear the petticoat. I think it helped a lot! I also really need to find a way to make my bangs nice and poofy like hers!
- Personal Thoughts:
- Because Alice in Wonderland is my favorite book, I knew I had to cosplay her one day! This cosplay is near and dear to my heart ♡ Also, the card soldiers are my boyfriend Paul (black) and our friend Chris (red)~
Wig Details
Add a Comment


text:
User Ratings
Featured Reviews
Highest Rated
This is by far the best image viewer program I've ever used! It's insanely fast, extremely minimal and well designed, and can open just about any kind of image file. It does everything I want it to with absolutely no fuss! If I were to offer one critique, it is that this program needs a configuration window. Editing a text file just doesn't cut it.
Lowest Rated
Nice project! You did a great job. Thank you!
User Reviews
While JPEGView bills itself as an image viewer, and it does that impressively well, I have found it quite useful for other tasks. It's great for tweaking the luminosity of my photographs, particularly in brightening shadows and darkening highlights. Of course, other software do that too but JPEGView 1.0.33 offers the greatest ease and flexibility. Particularly nice is seeing the histogram dynamically change as one moves the various sliders.
Simply the best image viewer for Windows
Awesome! Fastest editor I've ever seen. Great for large images. Extremely fast rotation of images. Immediately reflects changes made outside of the editor. At first I thought that it can't change contrast and brightness, but it can - you have to hover with the mouse over the bottom of the image. F1 is useful as well. Thank you!
Absolutely sublime software. This is everything I could want in a simple minimal image view/editor.
Very easy to use software yet powerful and fast. I like the minimal GUI that lets you watch the image without any annoying bars, menus, etc... . The developer did - and does - a great job.
EDITING FEATURE REQUIRED RED EYE REMOVAL... WHY IS IT NOT INCLUDED IN THE EDITING ?? otherwise.. it is the best picture handler i have come accross Also I agree with petecres..slideshow should have slower option than 5 fps option.. why not start from 1 fps... or enter a number of your choice option for fps slideshow ??
I am a software developper and write my own photo software. I was was using a Microsoft iPicture utility to display jpg photos, however that viewer was never as good as Photoshop or ACDSee's integrated viewers, so I have always been looking for a better viewer that I could integrate into my own code. JPEGView is just what I needed - it's very fast and displays better image quality than Photoshop, which was my reference until now. When you take 6000x4000 pixel photos with a Sony RX1 camera and have to display them on a monitor with 2560x1200 or less resolution you have a problem - you never see the great sharp image you took - until now! The image quality of JPEGView is better than anything I have seen. I can get the source code and integrate it into my work so for me so it's just perfect.
Lean and mean.... Does one thing and does it well.....and without the memory problems of some other apps when ripping through many, many files continuously...... Just two items on my personal wish list: a time setting for continuous display via holding PageDn. ..... When reviewing a couple thousand security cam alert .JPEGs, 5 FPS movie mode is too fast and 1 second between pictures in slide show mode is too slow. ..... That leaves holding the PageDn key, but that's also too fast...... Settings | PageDn Speed (in hundredths or thousandths of a second) would make this app five stars for me. I would probably set it to something like a half or quarter of a second...... The second wish list item is an optional notification and stop when the last image is being viewed - instead of looping around and starting over. Yeah... small potatoes.... but definately a nice-to-have...... the biggie is the time-between-pictures setting for PageDn.
I think I just fell in love with this. It's beautiful, fast and reliable and it has many built-in things that I like really much like settings for contrast and brightness etc. After messing with the settings I can hit CTRL + S and save the processed picture wherever I like. This comes very handy when you have to do just a couple of cosmetic changes to your picture.
Really nice work! Joins image quality and performance. It would be perfect if it had an OpenGL engine.
It looks nice, but... Srsly guys, it REALLY have no print function? Oh, it's a pity.
JPEGView is a must have program ever made. But I got a problem - when I delete image with this the image not gos to recycle bin !! It's delete forever. :( Is there any setting that can fix this problem?
great tool! Searched for something that could be customized (e.g. resize and save to current zoom-view). Has now replaced irfanview (one of my few propritary tools) for my most common tasks! Thx a lot :)
Fast; high quality decoding; valuable features; best all-around image viewer I've found for Windows
Fast, small and many features. Best I have seen. THANKS
This is by far the best image viewer program I've ever used! It's insanely fast, extremely minimal and well designed, and can open just about any kind of image file. It does everything I want it to with absolutely no fuss! If I were to offer one critique, it is that this program needs a configuration window. Editing a text file just doesn't cut it.
This is the absolute best program I have ever used to view and maintain my photo collections. It's just so fast and easy to use, simply perfect for me. This program is so awesome I created an account on sourceforge just to rate it. Beautiful job.
Optimal for eyes and photo management
Thank you for labor; this app is fastest,quality, small,quite simply, using and functional but not support printing document. This program is latest version added please printing documents. I wish you success. Thanks again. Best Regards.
Clean, fast, and easy to tweak via the UI or better yet in the well commented config file! PERFECT for viewing a series of images in glorious full screen, without giving up ANY of your tools/ options, much less ALL of your tools/ options as is the norm. After at least a decade I finally took the top 4 or 5 image file associations from my beloved Irfanview! Many thanks..
JPEGView is a VERY light, VERY fast, and VERY feature rich image viewer. I have tried about a dozen different image viewers, and none come even close to the speed, ease of use and simplicity of JPEGView. Get this software, and forget about everything else in this category.
Better than every other image viewer out there in terms of sheer flexibility and features
The best image viewer.
Absolutely incredible. The absolute best image viewer in existence for those who need an insane amount of customization for viewing images and animated gifs. I have searched high and low, and this one beats them all: HoneyView, IrfanView, Image Eye, XnView, Imagine, ACDSee, and many more. Get this portable image viewer and never ever look back.


text:
Tom Brady's Updated 2013 Fantasy Outlook and Trade Value After Week 4September 30, 2013
Tom Brady's performance against the Atlanta Falcons on Sunday at the Georgia Dome proves that he's still top-tier material in fantasy football.
Brady got off to a slow start this season in terms of fantasy football numbers, but he posted big numbers against the Falcons on Sunday, going 20-of-31 for 316 yards and two touchdowns. This was despite being without injured targets Rob Gronkowski and Danny Amendola.
Brady scored the fifth-most fantasy points (20) among quarterbacks in ESPN standard leagues on Sunday. He appears to be getting into a rhythm, developing a rapport with players like rookie Kenbrell Thompkins while he waits for Gronkowski and Amendola to return.
According to Jay Glazer of Fox, Gronkowski is targeting a Week 6 return. That would be just in time for what is sure to be a shootout against the New Orleans Saints in Foxborough. The impact of his return cannot be overstated. He was a top target for Brady last season and should greatly aid the veteran quarterback when he steps out onto the football field.
Brady faces the Cincinnati Bengals in Week 5. The Bengals have been strong against the pass for the most part this season, but they allowed Cleveland Browns quarterback Brian Hoyer to pass for 269 yards and two touchdowns on Sunday.
Based on performance up to this point, Brady would appear to have favorable fantasy matchups against the Denver Broncos (Week 12) and Baltimore Ravens (Week 16). For the most part, however, he faces some tough pass defenses throughout the season.
I don't expect him to post the same kind of numbers he did last season, so if you can get a top-tier quarterback with a favorable schedule in return, it may be worth a trade.


text:
Thursday, Aug. 15, 2013 | 2 a.m.
Sun coverage
The attendees at this year's National Clean Energy summit took many a gas-guzzling plane, cab and SUV to make it to Las Vegas' Mandalay Bay Resort, where they spent Tuesday comparing notes on the latest commercial technologies to reduce greenhouse gas emissions.
Sound ironic? Perhaps. But for now, conference organizers suggest, it is just one of the opportunity costs of getting the fledgling clean energy business going.
In the past few years, sustainable energy conference directors from the United Nations to the American Meteorological Society have either mandated or offered attendees the opportunity to offset their event-related carbon emissions, by investing the estimated cost of their "carbon footprint" directly into a sustainable energy project.
But since the Nevada-based Clean Energy Project took over the financials of the National Clean Energy Summit in 2011, they have eschewed the idea of offering participants a formal, centralized way of purchasing carbon offsets, reasoning that the purpose of the conference is like an offset itself.
"We use our limited resources to do direct advocacy for policies that help create renewable energy," CEP executive director Lydia Ball said.
Few of the conference organizers seemed aware of the carbon offsetting trend.
"This is the first I'm really hearing anything about it," said Camille Yameen, spokeswoman for the conference, while a spokeswoman for Sen. Harry Reid, chief conference organizer, asked for more clarification about what the Sun meant by carbon offsetting.
Carbon offsetting relies on estimating the amount of environmentally harmful carbon emissions one produces, or is at least responsible for, in the context of performing various activities, such as driving a car, flying in an airplane, or simply turning the lights on in their abode.
There are numerous carbon calculators online: the government's Environmental Protection Agency has a questionnaire to estimate household emissions, while more narrowly focused calculators estimate emissions for college students, certain types of businesses and even specific makes of automobiles.
Event planning is a popular area for carbon emissions estimates, as the fairly predictable combination of flights, hotel stays and in-town transportation offer a manageable way of measuring one's carbon footprint — and the pressure to offset that can more often be put on a company than an individual employee's checkbook.
For example, the event calculator at TerraPass.com estimates that a round-trip flight from Washington, D.C., to Las Vegas, plus two nights in a hotel, plus about 20 miles of in-city driving produces about 2,200 pounds of carbon dioxide. The site then estimates cost of offsetting that level of emissions is about $13-14.
But for the crowd in Las Vegas, coughing up even just a few extra dollars can be a tricky business.
While the conference attracted a few national consultants and developers, most conference attendees from outside of Nevada are government officials. When you add up the carbon footprints of the entourages for Reid, Energy Secretary Ernest Moniz, Interior Secretary Sally Jewell, and a small battery of current and former governors and members of Congress, the total of offsets could be a significant cash windfall for some worthy renewable energy project.
But using taxpayer dollars to pay for offsets at a time when the country is still divided over the harmfulness of carbon emissions or the technologies that produce them — especially at a time when deficits are high and budgets are tight — is a politically risky proposition.
Even within the growing community of climate change activists, there is dispute as to whether carbon offsetting, on an individual or collective basis, is really a deceptively false panacea.
Critics charge that carbon offsets do little to actually reduce the overall output of greenhouse gases, because the emitters are able to write off their sustainable environmental responsibility with a paycheck. Carbon offsets have even been compared to the sale of indulgences by the Catholic church — the rationale being that no level of investment in renewable energy projects will matter if the big emitters are given carte blanche to keep belching carbon byproducts into the air.
Still, official public policy on carbon offsets is divided. California recently green-lighted plans to let companies pay up to 8 percent of their required greenhouse gas reductions through carbon offsetting, while the European Union imposed a ban carbon-producing businesses using UN Certified Emissions Reductions to count toward emissions restrictions.
For now, clean energy conference organizers in Nevada are steering clear of the controversy and erring on the side of frugality, hoping that the clean energy work they are promoting — such as solar panel fields and clean-fuel cars — justifies the dirtier means of coming to the conference to display them and encourage others to take on similar projects.
"As you know, UNLV and MGM, both co-sponsors (of the conference), are currently developing renewable energy projects," Ball offered, referring to the solar and clean-fuel burning projects, in explaining why the National Renewable Energy conference didn't get into the business of carbon offsetting.


text:
We're really sorry but we've sold out of this product and are unable to obtain more stock. In most cases this is usually because the manufacturer has discontinued the product. We don't want you to miss out though so here's some of our best selling products which are similar to what you are looking for. Take a look and you could just find the perfect item. Just a small point to note - they might not have the exact features as the product you initially wanted so please be sure to check the features before you buy.
The NETGEAR NeoTV™ 550 Ultimate HD Media Player lets you bring all your digital media to your TV. Play movies, music, and photo collections stored on your networked devices (such as PC, Mac, and network attached storage). It also provides easy access to files stored on your USB drives and SD cards. It plays your digital movies in full high definition 1080p and stunning Dolby Digital or DTS surround sound, and automatically scans your networked and local devices, and lets you organize your movies, music, and photos. Live Browsing provides easy and fast access to your media collection.
The following resources are available for the NetGear NeoTV 550 Ultimate HD Media Player


text:
From Ottawa Citizen:
Saxophonist David S. Ware, a leading free jazz player during the last 20 years, died Thursday night. […]
Ware was 62. When he was 60, after nearly a decade of dialysis treatment, Ware underwent a kidney transplant. Ware's Wikipedia entry states that the operation took place after a kidney was donated in response to an email message sent out to nearly 1,000 of his fans. Aum Fidelity recently sent out this update on Ware's health, stating that he was"physically not doing well at all, though his spirit is in a very positive place." The update solicited cards and emails of support from Ware's fans to be shared with him.
• David S. Ware: http://www.davidsware.com
More about: David S. Ware


text:
We recommend upgrading to the latest Internet Explorer, Google Chrome, or Firefox.
Learn More
If you are using IE 9 or later, make sure you turn off "Compatibility View".
Handpicked brands for you
#tiendaonline #Pitimini #hechoamano #envioatodoelmundo ✈
Stay logged in
Forgot Password?
Or use these networks
New to GoodPeople?Create an account here!


text:
Girls will be Girls: Probe reveals students caused fire in Jeddah school
'Girls just wanna have fun' - even at school. But the consequences were not pretty for the Saudi girs' school in Jedda in November's fire.
The girls ignited the fire in the underground floor of the school while playing with a coal holder and then ran away from the scene to their classrooms when the blaze picked up, said Brig. Abdullah Jeddawi, director of Civil Defense in the city on Wednesday.
He said confessions of the students have been recorded in the presence of their parents and school authorities. "So far five students have acknowledged that they were behind the fire," a member from the investigation committee told Arab News.
The students are from Class III of the intermediate level. The students said they found a coal holder while playing inside the underground floor and used it to set fire to papers. They became afraid when the fire started spreading and ran away to their classrooms without informing the teachers or authorities.
The fire killed two teachers and injured 46 students.
Top Headlines
- Hero: Pakistan schoolboy, 14, sacrifices life to save classmates from suicide bomber
- Hijabi Siberian student told to de-scarf or get out
- Hell no! Texan parents won't abide pro-Islam lessons in their classrooms
- Two Teachers Die, Students saved: Another Saudi Girls' School Fire
- Hot for teacher? Omani students set classroom on fire


text:
The Evolving Story of Eli Aroch
A few moments after hitting the newsroom, the editors of Israel's business press knew the story was pure gold. In no time the reports on options speculator Eli Aroch's NIS 95 million arbitration award from Clal Finance Batucha were the hottest stories on TheMarker website. Readers also had what to say, too, and the number of talk-backs climbed sky-high.
What was it about the story that attracted such interest? First of all, it's a story about a little man who beat a giant corporation. Not just any corporate giant, but an insurance company, which always comes out on top of the little man.
Secondly, he beat the giant in its own home turf, namely the courtroom. Giant corporations, especially insurance companies, keep the costliest lawyers in the land on retainer, lawyers with the greatest experience in grinding down the little customer. Yet along comes Eli Aroch and manages to not only survive the system, but walk away with a stunning award in his favor.
Third, Aroch claimed to have formulated a brilliant strategy to make money from options traded on the stock market. Nobody engaged in securities could resist a story about buying, selling and winding up with tens of millions in hand.
Fourth of all, NIS 95 million is a nice round sum. It's big enough to cause a serious dent in even a giant corporation, and it's plenty big enough to ignite the imagination.
But it soon became apparent that the remarkable story of Eli Aroch was not going to end in the David vs Goliath genre. The first to realize as much were fellow traders in the market of options on the TA-25 index, which was Aroch's turf.
There are no free meals in the options market. There are no magic formulas. To earn amounts of money like that in such a short period of time requires the speculator to provide an enormous scope of guarantees. Aroch did not have that.
Change of plot
Suddenly the story about David and Goliath was turning into a story about the failure of Clal Finance's superstar lawyers and management.
Why had they agreed to an arbitrator who had no background in high finances? Hadn't they seen which way the wind was blowing, namely against them?
How could they become entangled in a ruling like that, knowing that arbitration rulings are almost impossible to overturn?
But before the legal story could gain momentum, whoops! turns out that the story is actually about Eli Aroch himself.
According to the motion to the court that Clal Finance Batucha submitted in hope of getting the award canceled, Aroch is no helpless little man in the street, he's a highly aggressive type who balked at nothing to get his. Threats, coercion, phone calls, revolving-door legal representation - Eli Aroch is no little dewy-eyed David, he's something else entirely.
Will the real Aroch please stand up
This is the stage at which the press and its readers started to wonder how Aroch really did persuade the arbitrator to award him that much, and at that point the story changed from "the case of Eli Aroch scandal" into "the case of Yakov Meltz ".
Did Meltz, a former Supreme Court justice, actually understand the case? To what degree is he cognizant of the financial markets? But Meltz wouldn't talk.
At this point the case of Eli Aroch turned into a PR war.
For Clal Finance Batucha and its parent company, IDB Holding Corporation, and that group's controlling shareholder, Nochi Dankner, this was more than a financial blow. This was humiliating.
Not only did they face paying a client NIS 95 million compensation, damages etc, but there was concern that the ruling resulted from unwise management of the case by Clal Finance Batucha.
Heavy guns
The result has been a bombardment of the press by the IDB group's PR agents and lawyers, not to mention phone calls, all designed to paint in black not only Aroch's name, but the logic underlying arbitration ruling itself.
At the start of the week, the IDB public-relations people started revving their engines with hints at a "bombshell", with Aroch's (or Meltz's) name on it. Then in mid-week the bomb landed, as Clal Finance filed its motion to cancel the award. The investment firm exposed transcripts of phone calls that indicated Meltz was admitting to having been threatened by Eli Aroch during the arbitration proceeding.
Websites celebrated the twist in the plot. The papers devoted whole pages and giant headlines telling about this judge who'd handed down a ruling despite being threatened by one of the parties.
True confessions
But is that confession of coercion the real story? That remains far from clear. It seems that the really interesting part of the story is how and where Meltz ostensibly admitted to being threatened: during a conversation with a private eye, who misrepresented herself as being a student working with kids in trouble. She had been sent by Clal Finance Batucha to ingratiate herself with Meltz.
Clal Finance sent her only after the ruling had been handed down, even though the company had suspected well beforehand that Aroch was threatening the judge.
Okay. Now it is not a story about David and Goliath, or a genius options trader, or the arbitrator who awarded an unheard of sum. It's a story about a giant concern prepared to do anything within law to reverse its loss.
Eli Aroch is a marginal figure in the capital market and few can really understand the financial and legal minutiae of his case.
But secretly taping a former justice is something that everybody can understand.
Taping conversations is quite the norm in the business world and in the world of law one too. When the taper is one o the parties to the conversation, it's perfectly legal.
But taping an ex-justice serving as an arbitrator is unprecedented, and many in the legal field feel the company has crossed the lines.
Will IsrAir's passengers remember in a year or two about the safety hazards revealed at the company? Probably not. But journalists, editors, publicists and big business will not be forgetting how an investigative report on IsrAir folded before Nochi Dankner, the airline's controlling shareholder, after Keshet chairman Mozi Wertheim intervened.
Will capital market players remember in a year or two how Eli Aroch did, or did not, rake in huge profits in the options market or why he was awarded the gigantic sum? Probably not. But judges, arbitrators, lawyers and businessmen won't be forgetting how Clal Finance Batucha, legally, managed to sweet-talk and tape a judge who'd ruled against it.
Did that Fact story about IsrAir need to be aired in a timely fashion? Perhaps. Was Eli Aroch entitled to that gigantic award? That question remains open too.
What will be remembered of both affairs is the ability of the companies controlled by the strongest businessman in the land to face off the papers and the legal system, and to employ any (legal) means at hand to gain their ends.
Want to enjoy 'Zen' reading - with no ads and just the article? Subscribe todaySubscribe now